Fortress Biotech (FBIO) news
Recent news
Fortress Biotech 2Q net income $0.6M
AInvest Wire · Aug 13, 2026Fortress Biotech 2Q loss/share 8.0c
AInvest Wire · Aug 13, 2026Fortress Biotech 2Q net revenue $18.7M
Fortress Biotech, Inc. (Nasdaq: FBIO) reported net revenue of $17.4 million for the second quarter of 2023, representing a 40% increase compared to $12.4 million in the first quarter of 2023. The company attributed this growth to strong performance from its marketed dermatology products and…
AInvest Wire · Aug 13, 2026Denali Therapeutics enters agreement to sell rare pediatric disease priority review voucher for $195 million
Denali Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million, according to recent disclosures. The PRV was awarded by the U.S. Food and Drug Administration (FDA) under the Rare Pediatric Disease PRV program, which incentivizes…
AInvest Wire · Jun 18, 2026Fortress Credit XLI CLO $443M+ new MM via Deutsche Bank priced
Fortress Investment Group has priced a new middle market Collateralized Loan Obligation (CLO), Fortress Credit XLI CLO, with a total size of $443 million, according to a recent transaction facilitated by Deutsche Bank. This issuance marks the latest addition to Fortress’s growing CLO platform,…
AInvest Wire · Jun 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.